Virexxa

Virexxa is a unique preparation being in clinical trials for treatment of advanced and relapsing forms of endometrial cancer, which action is based on increase of endometrial cancer sensitivity to hormonotherapy by means of induction of progesterone receptors in progesterone-tolerant endometrial cancer.
The OJSC "Pharmsynthez" fulfills the program of Virexxa clinical development investigating efficiency of combined application of Virexxa and progestins in patients with advanced and relapsing endometrial cancer who developed tolerance to progestins monotherapy. At the moment the phase II clinical trials of the preparation have been running in several clinical centers in the Russian Federation. Phase II clinical trials in the European Union countries will be started in 2011 after manufacture end of cGMP preparation series for clinical trials at the enterprise KeveltAS. OJSC “Pharmsynthez” has recently reported on the purchase of 100 % shares of this enterprise. The start of Virexxa clinical trials in the USA was formerly planned for 2012.